Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of FL058 in Healthy Chinese Subjects
NCT05055687Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pralubactam in bacterial infection (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Number of patients with adverse events. Started Jul 2020; status: completed.
02
Drugs
pralubactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05055687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055687.